Gastric cancer in Turkey - A bridge between West and East

Gastrointestinal Cancer Research

Volumn 3, Issue 1, 2009, Pages 29-32

  Yalcin, Suayib ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; TEGAFUR; URACIL;

ADJUVANT THERAPY; ADVANCED CANCER; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTINUOUS INFUSION; DIETARY INTAKE; FEBRILE NEUTROPENIA; GEOGRAPHIC DISTRIBUTION; HELICOBACTER INFECTION; HIGH RISK BEHAVIOR; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PUBLIC HEALTH PROBLEM; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; STOMACH CANCER; STOMACH SURGERY; SURGICAL TECHNIQUE; TURKEY (REPUBLIC);

EID: 77951733381     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Parkin DM, Bray F, Ferlay J, et al: Global Cancer Statistics, 2002. CA Cancer J Clin 55:74-108, 2005
2. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: cancer incidence. Mortality and prevalence worldwide. IARC cancer base no. 5, version 2.0, Lyon (France): IARC Press, 2004
3. Mackay J, Jemal A, Lee NC, et al: The Cancer Atlas. American Cancer Society, 2006
4. Karaoǧuz H, Içli H: Cancer problem in Türkiye. J Ankara Med School 15:547-558, 1993
5. Demirer T, Icli F, Uzunalimoglu Ö, et al: Diet and stomach cancer incidence: a case-control study in Turkey. Cancer 65:2344-2348, 1990
6. Firat D, Celik I: Cancer statistics in Turkey and in the world. 1993-1995. Turkish Association for Cancer Research and Control, Ankara, 1998
7. Tuncer I, Topcu N, Ugras S, et al: Van gölü havzasinda gastrointestinal kanserlerin daǧilimi; 1002 olgunun analizi. T Klin J Gastroenterohepatol 14:161-166, 2003
8. Türkdoǧan KM, Daǧoglu G, Akman N, et al: Dietary benzo(a)pyrene and 1,2-benzanthracene levels in an endemic upper gastrointestinal (oesophageal and gastric) cancer region of Turkey. J Nutr Environ Med 13:103-108, 2003
9. Türkdoǧan KM, Testereci H, Akman N, et al: Dietary nitrate and nitrite levels in an endemic upper gastrointestinal (esophageal and gastric) cancer region of Turkey. Turk J Gastroenterol 14:50-53, 2003
10. Yalcin B, Zengin N, Aydin F, et al: The clinical and pathological features of patients with gastric cancer in Turkey: A Turkish Oncology Group study. Turk J Cancer 36:108-115, 2006
11. Bor S, Vardar R, Ormeci N, et al: Prevalence patterns of gastric cancers in Turkey: model of a developing country with high occurrence of Helicobacter pylori. J Gastroenterol Hepatol 22: 2242-2245, 2007
12. Buǧra, D. Erken evre mide kanserine yaklaşim. Cerrahi ilkeler ve Türkiye'de durum. Mide tümörleri sempzyumu, Istanbul, 17-18 December 2004. Available at: http://www.medonk.com/ppt/ mts/Dursun_Bugra.ppt#256
13. Demirci S: Unpublished data, partly presented at the National Cancer Congress, Antalya, Turkey, 2003
14. Nazli O, Derici H, Tansug T, et al: Survival analysis after surgical treatment of gastric cancer: review of 121 cases. Hepatogastroenterol 54:625-629, 2007
15. Yildirim E, Celen O, Berberoglu U: The Turkish experience with curative gastrectomies for gastric carcinoma: is D-2 dissection worthwhile? J Am Coll Surg 192:25-37, 2001
16. Demir G, Buyukunal E, Kizilkilic E, et al: Gastric cancer in Turkey: a single center experience of 683 cases. J Clin Oncol 22(suppl 14), 2004, (abstr 4254)
17. Demir G, Ünsal D, Zengin N, et al: Opere 840 mide kanserli hastada prognostik faktorler. TOG Gastrointestinal Tümörler Grubu Çalişmasi, Medical Oncology Congress, Antalya; 2008, (abstr SB15)
18. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001
19. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
20. Boige V, Pignon J, Saint-Aubert B, et al: Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 25: 2007, (abstr 4510)
21. Icli F, Celik I, Aykan F, et al: A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer 83:2475-2480, 1998
22. Ajani JA, Moiseyenko VM, Tjulandin S, et al: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25:3205-3209, 2007
23. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007
24. Kiliçkap S, Ates Ö, Aksoy S, et al: Metastatik mide kanserinde taksoter-sisplatin-fluorourasil'in etkinlik analizi: diǧer tedavi rejimlerine göre saǧkalim avantaji saǧlar mi? II. Tibbi Onkoloji Kongresi, Antalya, 2008, (abstr 0 SB13)
25. Dank M, Zaluski J, Barone C, et al: Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemo therapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450-1457, 2008
26. Yalcin S, Roth A, Zalcberg JR, et al: Registry of gastric cancer treatment evaluation (REGATE): baseline characteristics of 10,299 patients from 22 countries, 2009 Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2009, (abstr 43)